Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Managed Care (Langhorne, Pa.)|June 15, 2011
Economic benefits of improved insulin stability in insulin pumpsRichard C Weiss, Derek van Amerongen, Gary Bazalo, et al.Clinical Therapeutics|April 28, 2009
A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetesBijan J Borah, Theodore Darkow, Jonathan Bouchard, et al.Current Medical Research and Opinion|May 25, 2010
Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methodsOzgur Tunceli, Ron Wade, Tao Gu, et al.Journal of Occupational and Environmental Medicine|December 3, 2009
Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005Emily D Durden, Berhanu Alemayehu, Jonathan R Bouchard, et al.Allergy and Asthma Proceedings|December 28, 2020
Real-world mapping of allergy immunotherapy in the United States: The argument for improving adherenceBrian Stone, Karen Rance, Douglas Waddell, et al.Diabetes Care|March 23, 2011
Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetesStephen S Johnston, Christopher Conner, Mark Aagren, et al.Advances in Therapy|June 24, 2008
Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomesWilliam J Valentine, Gordon Goodall, Mark Aagren, et al.Clinical Therapeutics|November 25, 2010
Does type of bolus insulin matter in the hospital? Retrospective cohort analysis of outcomes between patients receiving analogue versus human insulinKelly J Ko, Veronica Tomor, Brian H Nathanson, et al.Patient Preference and Adherence|November 25, 2021
Preference for Immunotherapy with Tablets by People with Allergic RhinitisMike Tankersley, Tonya Winders, Mark Aagren, et al.Current Medical Research and Opinion|September 7, 2021
Subcutaneous immunotherapy takes more than the time in the clinicMike Tankersley, Tonya Winders, Mark Aagren, et al.Pageof 4